ReviewMaterials (Basel, Switzerland)2022
Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma.
Review in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Graphene Quantum Dots in Cancer Diagnostics and Therapeutics: Advances in Biosensing, Imaging, and Treatment Applications.Current medical science · 2026Review
- Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions.Cancers · 2025Review
- Biomembrane-coated nanosystems as next-generation delivery systems for the treatment of gastrointestinal cancers.Bioengineering & translational medicine · 2025Review
- Graphene Oxide Nanoparticles for Photothermal Treatment of Hepatocellular Carcinoma Using Low-Intensity Femtosecond Laser Irradiation.Molecules (Basel, Switzerland) · 2024Article
- Application of nanotechnology in the treatment of hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
- Research progress of nanoparticles in diagnosis and treatment of hepatocellular carcinoma.Open life sciences · 2024Review
- Nanotechnology for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2024Review
- Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma.Journal of nanobiotechnology · 2023Review
- PEGylated Liposomes Loaded with Carbamate Inhibitor ANP0903 Trigger Apoptosis by Enhancing ER Stress in HepG2 Cancer Cells.International journal of molecular sciences · 2023Article
- Frontiers in hepatic drug delivery-grand challenges.Frontiers in drug delivery · 2023Article
- Interventional nanotheranostics in hepatocellular carcinoma.Nanotheranostics · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma is the most common liver malignancy and is among the top five most common cancers. Despite the progress of surgery and chemotherapy, the results are often disappointing, in part due to chemoresistance. This type of tumor has special characteristics that allow the improvement of diagnostic and treatment techniques used in clinical practice, by combining nanotechnology. This article presents a brief review of the literature focused on nano-conditioned diagnostic methods, targeted therapy, and therapeutic implications for the pathology of hepatocellular carcinoma. Within each subdomain, several modern technologies with significant impact were highlighted: serological, imaging, or histopathological diagnosis; intraoperative detection; carrier-type nano-conditioned therapy, thermal ablation, and gene therapy. The prospects offered by nanomedicine will strengthen the hope of more efficient diagnoses and therapies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.